Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition?

Biologics: Targets and Therapy

Volumn 8, Issue , 2014, Pages 59-65

  Siltari, Aino ^a   Viitanen, Riikka ^b   Kukkurainen, Sampo ^b   Vapaatalo, Heikki ^a   Valjakka, Jarkko ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

ACE inhibition; Autodock modeling; Ile Pro Pro; Val Pro Pro; Vascular function

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 1; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOLEUCYLPROLYLPROLINE PEPTIDE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE PEPTIDE;

ARTICLE; CHEMICAL BOND; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION;

EID: 84896847366     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S54056     Document Type: Article

References (46)

1. Jäkälä P, Vapaatalo H. Antihypertensive peptides from milk proteins. Pharmaceuticals. 2010;3(1):251-272.
2. Turpeinen AM, Järvenpää S, Kautiainen H, Korpela R, Vapaatalo H. Antihypertensive effects of bioactive tripeptides-a random effects meta-analysis. Ann Med. 2013;45(1):51-56.
3. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes 1 (ACE1) and 2 (ACE2) and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther. 2009;25(1):23-28.
4. Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML. Long-term intake of milk peptide attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol. 2001;52(4 Pt2):745-754.
5. Jäkälä P, Hakala A, Turpeinen AM, Korpela R, Vapaatalo H. Casein-derived bioactive tripeptides Ile-Pro-Pro and Val-Pro-Pro attenuate the development of hypertension and improve endothelial function in salt-loaded Goto-Kakizaki rats. J Funct Foods. 2009;1(4):366-374.
6. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 1995;78(4):777-783.
7. Nakamura Y, Yamamoto N, Sakai K, Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors of angiotensin I-converting enzyme. J Dairy Sci. 1995;78(6):1253-1257.
8. Xu JY, Qin LQ, Wang PY, Li W, Chang C. Effects of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition. 2008;24(10):933-940.
9. Cicero AFG, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effects of lactotripeptides assumed as functional food: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25(7):425-436.
10. Turpeinen AM, Järvenpää S, Kautiainen H, Korpela R, Vapaatalo H. Antihypertensive effects of bioactive tripeptides-a random effects meta-analysis. Ann Med. 2013;45(1):51-56.
11. Jäkälä P, Jauhiainen T, Korpela R, Vapaatalo H. Milk protein-derived bioactive tripeptides Ile-Pro-Pro and Val-Pro-Pro protect endothelial function in vitro in hypertensive rats. J Funct Foods. 2009;1(3): 266-273.
12. Jauhiainen T, Pilvi T, Cheng ZJ, et al. Milk products containing bioactive tripeptides have an antihypertensive effect in double transgenic rats (dTGR) harbouring human renin and human angiotensinogen genes. J Nutr Metab. 2010;(2010);Article ID287030, 6 pages.
13. Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML. Effect on long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res. 2002;69(1):103-111.
14. Lehtinen R, Jauhiainen T, Kankuri E, et al. Effects of milk casein-derived tripeptides Ile-Pro-Pro, Val-Pro-Pro, and Leu-Pro-Pro on enzymes processing vasoactive precursors in vitro. Arzneimittelforschung. 2010;60(4):182-185.
15. Jäkälä P, Pere E, Lehtinen R, Turpeinen A, Korpela R, Vapaatalo H. Cardiovascular activity of milk-casein-derived tripeptides and plant sterols in spontaneously hypertensive rats. J Phys Pharm. 2009;60(4): 11-20.
16. Jauhiainen T, Collin M, Narva M, et al. Effect of long-term intake of milk peptides and minerals on blood pressure and arterial function in spontaneously hypertensive rats. Milk Sci Int. 2005;60(4):358-363.
17. Siltari A, Kivimäki AS, Ehlers PI, Korpela R, Vapaatalo H. Effects of milk casein derived tripeptides on endothelial enzymes in vitro; a study with synthetic tripeptides. Arzneimittelforschung. 2012;62(10):477-481.
18. Ehlers PI, Nurmi L, Turpeinen AM, Korpela R, Vapaatalo H. Casein-derived tripeptide Ile-Pro-Pro improves angiotensin-(1-7)-and bradykinin-induced rat mesenteric artery relaxation. Life Sci. 2011:88(5-6);206-211.
19. Fernandes L, Fortes ZB, Nigro D, Tostes RCA, Santos RAS, Catelli De Carvalho MH. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 2001;37(2 Pt 2):703-709.
20. Ueda S, Masumori-Meamoto S, Wada A, Ishii M, Brosnihan IB, Umemura S. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens. 2001;19(11):2001-2009.
21. Espín JC, García-Ruiz PA, Tudela J, García-Cánovas F. Study of stereospecificity in mushroom tyrosinase. Biochem J. 1998;331(Pt 2): 547-551.
22. Qu N, Ignatenko NA, Yamauchi P, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J. 2003;375(Pt 2):465-470.
23. 13C nuclear magnetic resonance study of the cis-trans isomerism in X-Pro-Pro tripeptides. Biochemistry. 1978;17(12):2277-2283.
24. Berman HM, Westbrook J, Feng F, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-242.
25. Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem. 2009;30(16):2785-2791.
26. Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature. 2003;421(6922):551-554.
27. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-2723.
28. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781-1802.
29. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparision of multiple amber force fields and development of improved protein backbone parameters. Proteins. 2006;65(3):712-725.
30. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9): 1157-1174.
31. Porter CT, Bartlett GJ, Thornton JM. The Catalytic Site Atlas: a resource of catalytic sites and residues identified in enzymes using structural data. Nucl Acids Res. 2004;32(Database issue):D129-D133.
32. Siow RC. Culture of human endothelial cells from umbilical veins. Methods Mol Biol. 2012;806:265-274.
33. Marin V, Kaplanski G, Gres S, Farnarier C, Bongrand P. Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells. J Immunol Methods. 2001;254(1-2):183-190.
34. Santos RA, Krieger EM, Greene LJ. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension. 1985;7(2):244-252.
35. Rubin B, Antonaccio MJ, Goldberg ME, et al. Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats. Eur J Pharmacol. 1978;51(4):377-388.
36. Vollmer RR, Boccagno JA, Steinbacher TE, Horovitz ZP, Murthy VS. Antihypertensive effects of captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme in conscious two kidney perinephritic hypertensive dogs. J Pharmacol Exp Ther. 1981;216(2):225-231.
37. Mutter M, Wöhr T, Gioria S, Keller M. Pseudo-prolines: Induction of cis/trans-conformational interconversion by decreased transition state barriers. Biopolymers. 1999;51(2):121-128.
38. Schmid FX, Grafl R, Wrba, Beintema JJ. Role of proline peptide bond isomerization in unfolding and refolding of ribonuclease. Proc Natl Acad Sci U S A. 1986;83(4):872-876.
39. Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure. Result on double-blinded randomiced controlled trial. Hypertension. 2008;51(2):399-405.
40. Van der Zander K, Bots ML, Bak AA, Koning MM, de Leeuw PW. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Amer J Clin Nutr. 2008;88(6):1697-1702.
41. Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens. 2009;27(7): 1404-1409.
42. Countermann A, Clemmer DE. Cis-Trans signatures of proline-containing tryptic peptides in the gas phase. Anal Chem. 2002;74(9): 1946-1951.
43. Korhonen H. Milk-derived bioactive peptides: From science to applications. J Funct Foods. 2009;1(2):177-187.
44. Foltz M, van Buren L, Klaffke W, Duchateau GS. Modeling of the relationship between dipeptide structure and dipeptide stability, permeability, and ACE inhibition activity. J Food Sci. 2009;74(7): H243-H251.
45. Meyer RF, Essenburg AD, Smith RD, Kaplan HR. Angiotensin converting enzyme inhibitors: modification of a tripeptide analogue. J Med Chem. 1982;25(8):996-999.
46. Jäkälä P, Turpeinen AM, Rajakari K, Korpela R, Vapaatalo H. Biological effects of casein-derived tripeptides powders are not affected by fermentation process. Int Dairy J. 2010;20(5):366-370.